1. Home
  2. CINGW vs INSW Comparison

CINGW vs INSW Comparison

Compare CINGW & INSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • INSW
  • Stock Information
  • Founded
  • CINGW N/A
  • INSW 1999
  • Country
  • CINGW United States
  • INSW United States
  • Employees
  • CINGW 13
  • INSW N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • INSW Semiconductors
  • Sector
  • CINGW Health Care
  • INSW Technology
  • Exchange
  • CINGW Nasdaq
  • INSW Nasdaq
  • Market Cap
  • CINGW N/A
  • INSW N/A
  • IPO Year
  • CINGW 2021
  • INSW N/A
  • Fundamental
  • Price
  • CINGW $0.09
  • INSW $51.99
  • Analyst Decision
  • CINGW
  • INSW Strong Buy
  • Analyst Count
  • CINGW 0
  • INSW 3
  • Target Price
  • CINGW N/A
  • INSW $68.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • INSW 549.5K
  • Earning Date
  • CINGW N/A
  • INSW 11-05-2024
  • Dividend Yield
  • CINGW N/A
  • INSW 11.20%
  • EPS Growth
  • CINGW N/A
  • INSW N/A
  • EPS
  • CINGW N/A
  • INSW 10.49
  • Revenue
  • CINGW N/A
  • INSW $1,024,252,000.00
  • Revenue This Year
  • CINGW N/A
  • INSW $0.49
  • Revenue Next Year
  • CINGW N/A
  • INSW N/A
  • P/E Ratio
  • CINGW N/A
  • INSW $4.96
  • Revenue Growth
  • CINGW N/A
  • INSW N/A
  • 52 Week Low
  • CINGW N/A
  • INSW $42.08
  • 52 Week High
  • CINGW N/A
  • INSW $65.94
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • INSW 50.92
  • Support Level
  • CINGW N/A
  • INSW $51.68
  • Resistance Level
  • CINGW N/A
  • INSW $54.84
  • Average True Range (ATR)
  • CINGW 0.00
  • INSW 1.04
  • MACD
  • CINGW 0.00
  • INSW 0.09
  • Stochastic Oscillator
  • CINGW 0.00
  • INSW 39.94

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: